Omega-3 Polyunsaturated Fatty Acids Supplementation Alleviate Anxiety Rather Than Depressive Symptoms Among First-Diagnosed, Drug-Naïve Major Depressive Disorder Patients: A Randomized Clinical Trial
- PMID: 35903448
- PMCID: PMC9315396
- DOI: 10.3389/fnut.2022.876152
Omega-3 Polyunsaturated Fatty Acids Supplementation Alleviate Anxiety Rather Than Depressive Symptoms Among First-Diagnosed, Drug-Naïve Major Depressive Disorder Patients: A Randomized Clinical Trial
Abstract
Background: Omega-3 polyunsaturated fatty acids (n-3 PUFAs) augmentation of antidepressants has shown great potential in the prevention and treatment of major depressive disorders (MDD).
Objective: To investigate the effect of n-3 PUFAs plus venlafaxine in patients with first-diagnosed, drug-naïve depression.
Method: A total of 72 outpatients with first-diagnosed depression were recruited. The daily dose of 2.4 g/day n-3 PUFAs or placebo plus venlafaxine was used for over 12 weeks. The outcomes were assessed by the Hamilton depression scale (HAMD), Hamilton anxiety scale (HAMA), Beck depression inventory (BDI), and Self-rating anxiety scale (SAS).
Results: Both groups exhibited improvement on clinical characteristics at week 4 and week 12 compared with baseline. The rate of responders for anxiety in n-3 PUFAs group (44.44%) was significantly higher than that in placebo group (21.21%) at week 4 (χ2 = 4.182, p = 0.041), while week 12 did not show a difference (χ2 = 0.900, p = 0.343). The rate of responders for depression at both week 4 (χ2 = 0.261, p = 0.609) and week 12 (χ2 = 1.443, p = 0.230) showed no significant difference between two groups. Further analysis found that Childhood Trauma Questionnaire (CTQ) had positive correlation with HAMA (r = 0.301, p = 0.012), SAS (r = 0.246, p = 0.015), HAMD (r = 0.252, p = 0.038) and BDI (r = 0.233, p = 0.022) with Pearson correlation analysis. Social Support Rating Scale (SSRS) had negative correlation with SAS (r = -0.244, p = 0.015) and BDI (r = -0.365, p = 0.000).
Conclusion: This trial found that n-3 PUFAs supplementation in favor of venlafaxine alleviated the anxiety symptoms rather than depressive symptoms at the early stage of treatment (4 weeks) for first-diagnosed, drug-naïve depressed patients. However, the advantage disappeared in long-term treatment. Furthermore, childhood abuse and social support are closely related to the clinical and biological characteristics of depression. Both childhood trauma and lack of social support might be predictors of poor prognosis in depression.
Clinical trial registration: [clinicaltrials.gov], identifier [NCT03295708].
Keywords: antidepressant; childhood abuse; major depressive disorders; nutrient intervention; omega-3 polyunsaturated fatty acids; social support.
Copyright © 2022 Yang, Wang, Jin, Cao, Wu, Guo, Chen, Tang and Tang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Effects of childhood trauma on depression and cognitive function in first-diagnosed, drug-naïve depressed patients: an observational case-control study.BMC Psychiatry. 2025 Apr 3;25(1):329. doi: 10.1186/s12888-025-06764-w. BMC Psychiatry. 2025. PMID: 40181288 Free PMC article.
-
Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder - Results from a randomized controlled trial.Brain Behav Immun. 2020 Mar;85:14-20. doi: 10.1016/j.bbi.2019.03.012. Epub 2019 Mar 19. Brain Behav Immun. 2020. PMID: 30902738 Clinical Trial.
-
Omega-3 polyunsaturated fatty acids supplementation improves memory in first-diagnosed, drug-naïve patients with depression: Secondary analysis of data from a randomized controlled trial.J Affect Disord. 2024 Apr 1;350:403-410. doi: 10.1016/j.jad.2024.01.149. Epub 2024 Jan 18. J Affect Disord. 2024. PMID: 38244783 Clinical Trial.
-
Omega-3 PUFAs' efficacy in the therapy of coronary artery disease combined with anxiety or depression: a meta-analysis.Front Psychiatry. 2024 Jun 24;15:1368007. doi: 10.3389/fpsyt.2024.1368007. eCollection 2024. Front Psychiatry. 2024. PMID: 38979505 Free PMC article.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
Cited by
-
The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.Nutrients. 2024 Oct 29;16(21):3688. doi: 10.3390/nu16213688. Nutrients. 2024. PMID: 39519521 Free PMC article. Clinical Trial.
-
Sex differences in erythrocyte fatty acid composition of first-diagnosed, drug-naïve patients with major depressive disorders.Front Pharmacol. 2023 Dec 18;14:1314151. doi: 10.3389/fphar.2023.1314151. eCollection 2023. Front Pharmacol. 2023. PMID: 38164472 Free PMC article.
-
Omega-3 fatty acid supplementation for depression in children and adolescents.Cochrane Database Syst Rev. 2024 Nov 20;11(11):CD014803. doi: 10.1002/14651858.CD014803.pub2. Cochrane Database Syst Rev. 2024. PMID: 39564892
-
Effects of childhood trauma on depression and cognitive function in first-diagnosed, drug-naïve depressed patients: an observational case-control study.BMC Psychiatry. 2025 Apr 3;25(1):329. doi: 10.1186/s12888-025-06764-w. BMC Psychiatry. 2025. PMID: 40181288 Free PMC article.
-
Effects of fish oil supplementation on bone turnover markers in depression: a pilot study.Front Nutr. 2024 Dec 12;11:1464526. doi: 10.3389/fnut.2024.1464526. eCollection 2024. Front Nutr. 2024. PMID: 39726877 Free PMC article.
References
Associated data
LinkOut - more resources
Full Text Sources
Medical